Please try another search
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Name | Age | Since | Title |
---|---|---|---|
Frank Joseph Daugherty | 73 | 2019 | Chief Medical Officer & Director |
Kenneth Hallock | 75 | 2019 | Independent Director |
David B. McWilliams | 79 | 2009 | Independent Chairman of the Board |
Snehal S. Patel | 60 | 2010 | CEO, CFO & Director |
Eric Rothe | 48 | 2006 | Founder & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review